Floatz logo

Atezolizumab

Ovarian Endometrioid Tumor

University Health Network, Torontomonoclonal_antibodyPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Ovarian Endometrioid Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →